July 17-19, 2020
AT-007: Development of an Oral Treatment for Patients with Galactosemia
Presented by Shoshana Shendelman, PhD, CEO and Founder, Applied Therapeutics
AT-007: Development of an Oral Treatment for Patients with Galactosemia
Presented by Shoshana Shendelman, PhD, CEO and Founder, Applied Therapeutics
Galactosemia Foundation Conference
ACTION-Galactosemia: Clinical Experience with Adult Galactosemia Patients and Path Forward
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer, Applied Therapeutics
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer, Applied Therapeutics
Galactosemia Foundation Conference
ACTION-Galactosemia Kids: Pediatric Study of AT-007 in Children with Galactosemia
Presented by Shoshana Shendelman, PhD, CEO and Founder, Applied Therapeutics
Presented by Shoshana Shendelman, PhD, CEO and Founder, Applied Therapeutics
Galactosemia Foundation Conference
April 28, 2020
Applied Therapeutics Galactosemia Educational Symposium
Presented by Dr. Shoshana Shendelman, PhD & Dr. Riccardo Perfetti, MD, PhD
Applied Therapeutics Galactosemia Educational Symposium
Presented by Dr. Shoshana Shendelman, PhD & Dr. Riccardo Perfetti, MD, PhD
Moderated by Dr. Eva-Kozicz, MD, PhD
December 5-7, 2019
The ARISE-HF Study — Development of AT-001 for the Treatment of Diabetic Cardiomyopathy: Rationale and Study Design
Presented by Dr. James Januzzi, MD
The ARISE-HF Study — Development of AT-001 for the Treatment of Diabetic Cardiomyopathy: Rationale and Study Design
Presented by Dr. James Januzzi, MD
Aldose Reductase Inhibitors: AT-001 a Next Generation Aldose Reductase Inhibitor in Development for Diabetic Cardiomyopathy (DbCM)
Presented by Dr. Francesca Lawson, MD, FAHA
Presented by Dr. Francesca Lawson, MD, FAHA
16th Global Cardio Vascular Clinical Trialists (CVCT) Forum
Washington, D.C.
December 4-7, 2019
Overcoming the Safety Challenges of Aldose Reductase Inhibition: Development of AT-001 for Diabetic Cardiomyopathy (poster)
Overcoming the Safety Challenges of Aldose Reductase Inhibition: Development of AT-001 for Diabetic Cardiomyopathy (poster)
Overcoming the Safety Challenges of Aldose Reductase Inhibition: Development of AT-001 for Diabetic Cardiomyopathy (presentation)
World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
Los Angeles, CA
November 16-18, 2019
Clinical Assessment of AT-001, an Aldose Reductase Inhibitor in Development for Diabetic Cardiomyopathy: a 28 Day Proof of Concept Study
Clinical Assessment of AT-001, an Aldose Reductase Inhibitor in Development for Diabetic Cardiomyopathy: a 28 Day Proof of Concept Study
American Heart Association (AHA) Scientific Session 2019
Philadelphia, Pennsylvania
American Society of Human Genetics (ASHG) 2019 Annual Meeting
Houston, Texas
September 16-20, 2019
AT‑001 Significantly Reduces Cardiac Damage in an Animal Model of Diabetic Cardiomyopathy
AT‑001 Significantly Reduces Cardiac Damage in an Animal Model of Diabetic Cardiomyopathy
55th Annual Meeting of the European Association for the Study of Diabetes (EASD)
Barcelona, Spain
September 13-16, 2019
Preclinical and Clinical Proof of Concept for Metabolic Intervention in Diabetic Cardiomyopathy
Preclinical and Clinical Proof of Concept for Metabolic Intervention in Diabetic Cardiomyopathy
Heart Failure Society of America (HFSA) 23rd Annual Scientific Meeting
Philadelphia, PA
June 7-11, 2019
Phase 1/2 Safety and Proof of Biological Activity Study of AT-001, an Aldose Reductase Inhibitor in Development for Diabetic Cardiomyopathy
Phase 1/2 Safety and Proof of Biological Activity Study of AT-001, an Aldose Reductase Inhibitor in Development for Diabetic Cardiomyopathy
American Diabetes Association 79th Scientific Sessions
San Francisco, CA
May 25-28, 2019
Beneficial effects of AT-001, an aldose reductase inhibitor, in rodent models of Diabetic Cardiomyopathy
European Society for Cardiology 6th World Congress on Acute Heart Failure
Athens, Greece
October 15-16, 2018
A Novel Investigational Treatment In Preclinical Development For Galactosemia
NORD Rare Summit 2018
Washington, D.C.